Home Tags Mylan
A huge lawsuit accuses nearly 20 big drug companies, a billionaire, and 2 brothers-in-law of cozying up to hike drug prices. Here’s the inside s...
Business Insider is the first to report on the unredacted suit, which alleges frequent, close communications among employees of rival companies about how to increase prices.
Drug giant Novartis is gearing up to release a cheaper EpiPen rival, but one big factor may make competition tricky
The Thursday announcement shows an end in sight for the 17-month saga that has stretched since Symjepi was first approved by U.S. regulators.
The strange history of the EpiPen, the device developed by the military that turned into a billion-dollar business and now faces generic competition b...
Here's the story of how a common, lifesaving device became a controversial drug-pricing story, facing recalls, shortages, and now generic competition between Mylan and Teva.
Mylan stock dropped over 7% after it released its second quarter earning report. The company then announced that it was to undergo a strategic review.
The FDA on Wednesdsay said that there's a shortage of EpiPens in the US. Mylan, the company that distributes the emergency allergy medication, said that there are "intermittent supply constraints," but supply is available.
BI PRIME: Morgan Stanley compiled a list of large and liquid companies it thinks will get at least one tender offer over the next 12 months.
A lawsuit over price fixing by drugmakers is being massively expanded and shares of Mylan are plunging
The states are zeroing in on a man named Rajiv Malik, Mylan's president and executive director, along with Satish Mehta, CEO at Emcure Pharmaceuticals.
The FDA just approved a ‘complex generic drug’ and it’s sending one stock soaring and another crashing
The FDA on Tuesday approved a generic version of Copaxone, a drug that treats multiple sclerosis that generates about $3 billion in sales.
Mylan increased the price of a lifesaving Epipen 50%.
Mylan’s shareholders just voted against its executive pay, which included a $100 million package for its chairman
Mylan shareholders voted to re-elect the generic drugmaker's board at its annual meeting on Thursday, despite a push to to vote down most of the directors.